An overview of benefits and risks of chronic melanocortin‐1 receptor activation

Documenti analoghi

• Treatment refractory chronic spontaneous urticaria may benefit from treatment with dupilumab: A case series of eight patients
  di: S. E. B. Feldborg, et al.
  Pubblicazione: (2024)
• Systemic neurokinin‐1 receptor antagonists mitigate chronic pruritus: A systematic review and meta‐analysis
  di: Pei‐Yun Ho, et al.
  Pubblicazione: (2025)
• EADV Task Force Pruritus White Paper on chronic pruritus and chronic prurigo: Current challenges and future solutions
  di: S. Ständer, et al.
  Pubblicazione: (2024)
• Acceptability and perceived benefits of validated pruritus assessment instruments in the dermatological office and clinic: The perspectives of patients and physicians
  di: M. P. Pereira, et al.
  Pubblicazione: (2024)
• Increased expression of in situ CD123 and reduced Toll‐like receptor 7/9 signalling pathway suggest impaired activation of plasmacytoid dendritic cells in recurrent erythema multiforme
  di: N. F. Dias de Oliveira, et al.
  Pubblicazione: (2024)